Abstract
Vascular angiogenesis has been shown to play a key role in many solid tumors. The vascular endothelial growth factor (VEGF) isoforms and their tyrosine kinase receptors (VEGFRs) have been under intense research for effective anticancer drug candidates. Epidermal growth factor (EGF) and its receptor (EGFR) provide another pathway critical in monitoring angiogenesis. VEGF exerts its effect through binding to tyrosine kinase receptors, mainly VEGFR-1 (Flt-1, the fms-like tyrosine kinase-1) and VEGFR-2 (Flk-1/KDR, fetal liver kinase-1). This paper reviews the progress, mechanism, and binding modes of recently approved kinase inhibitors, such as sunitinib (Sutent®), sorafenib (Nexavar®) and dasatinib (Sprycel®), as well as other inhibitors that are still under clinical development. Recent clinical treatments suggest that most inhibitors of VEGFR (and/or EGFR) exert their therapeutic effect through not only targeting the VEGFR (and/or EGFR) pathway, but also inhibiting other pathways, such as RAF/MEK/ERK pathway. A new pharmacophore model for second generation of type II tyrosine kinase inhibitors and recent advances in the combination of VEGFR tyrosine kinase inhibitors and other chemotherapeutics are also covered.
Keywords: VEGFR, kinase inhibitor
Current Topics in Medicinal Chemistry
Title: Molecular Design and Clinical Development of VEGFR Kinase Inhibitors
Volume: 7 Issue: 14
Author(s): Zhong Haizhen and Bowen Phillip J.
Affiliation:
Keywords: VEGFR, kinase inhibitor
Abstract: Vascular angiogenesis has been shown to play a key role in many solid tumors. The vascular endothelial growth factor (VEGF) isoforms and their tyrosine kinase receptors (VEGFRs) have been under intense research for effective anticancer drug candidates. Epidermal growth factor (EGF) and its receptor (EGFR) provide another pathway critical in monitoring angiogenesis. VEGF exerts its effect through binding to tyrosine kinase receptors, mainly VEGFR-1 (Flt-1, the fms-like tyrosine kinase-1) and VEGFR-2 (Flk-1/KDR, fetal liver kinase-1). This paper reviews the progress, mechanism, and binding modes of recently approved kinase inhibitors, such as sunitinib (Sutent®), sorafenib (Nexavar®) and dasatinib (Sprycel®), as well as other inhibitors that are still under clinical development. Recent clinical treatments suggest that most inhibitors of VEGFR (and/or EGFR) exert their therapeutic effect through not only targeting the VEGFR (and/or EGFR) pathway, but also inhibiting other pathways, such as RAF/MEK/ERK pathway. A new pharmacophore model for second generation of type II tyrosine kinase inhibitors and recent advances in the combination of VEGFR tyrosine kinase inhibitors and other chemotherapeutics are also covered.
Export Options
About this article
Cite this article as:
Haizhen Zhong and J. Phillip Bowen, Molecular Design and Clinical Development of VEGFR Kinase Inhibitors, Current Topics in Medicinal Chemistry 2007; 7 (14) . https://dx.doi.org/10.2174/156802607781696855
DOI https://dx.doi.org/10.2174/156802607781696855 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy
Current Drug Metabolism Flavonoids in the Treatment of Diabetes: Clinical Outcomes and Mechanism to Ameliorate Blood Glucose Levels
Current Diabetes Reviews Pharmacophore Generation and 3D-QSAR of Novel 2-(quinazolin-4- ylamino)-[1,4] Benzoquinone Derivatives as VEGFR-2 Inhibitors
Letters in Drug Design & Discovery A Review of Coumarin Derivatives in Pharmacotherapy of Breast Cancer
Current Medicinal Chemistry Association of ATG7 Polymorphisms and Clear Cell Renal Cell Carcinoma Risk
Current Molecular Medicine Recent Anticancer Cytotoxic Agents
Current Medicinal Chemistry - Anti-Cancer Agents Suppression of Erosive Arthritis by NF-κB Inhibitors
Current Rheumatology Reviews Chronic Exposure to Low-Level Cadmium in Diabetes: Role of Oxidative Stress and Comparison with Polychlorinated Biphenyls
Current Drug Targets Molecular Imaging with Small Animal PET/CT
Current Medical Imaging Quantitative Structure-Activity Relationship Studies: Understanding the Mechanism of Tyrosine Kinase Inhibition
Current Enzyme Inhibition Targeting Nodal and Cripto-1: Perspectives Inside Dual Potential Theranostic Cancer Biomarkers
Current Medicinal Chemistry Role of Infection Control in Prevention of Hepatitis B virus (HBV) in Hemodialysis (HD) Patients.
Infectious Disorders - Drug Targets Advancements in Adjuvanticity of Bioactive Inorganic and Organic Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes?
Current Pharmacogenomics and Personalized Medicine The Anti-cancer Actions of Vitamin D
Anti-Cancer Agents in Medicinal Chemistry Calpains: Attractive Targets for the Development of Synthetic Inhibitors
Current Topics in Medicinal Chemistry Anti-Angiogenesis and RGD-Containing Snake Venom Disintegrins
Current Pharmaceutical Design The Controlled Release of Drugs and Bioactive Compounds from Mesoporous Silica Nanoparticles
Current Drug Delivery Approaches for Imaging the Diabetic Pancreas: First Results
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Antioxidant Mechanisms in Nonalcoholic Fatty Liver Disease
Current Drug Targets